China's medical products administrator granted Hansoh Pharmaceutical (HKG:3692) breakthrough therapy designation for its HS-20089 injection for certain types of ovarian, fallopian tube, or peritoneal cancer.
The company applied for the designation for platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, according to a Thursday filing with the Hong Kong bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.